Pharmacodynamics of progesterone women, this effect being the result of suppression of the mid-cycle surge in gonadotropin secretion, is 300 mg/day. However, this figure is based on limited clinical data. Conversely, treatment with a high dosage of oral progesterone of 100 mg four times per day (or 400 mg/day total) in men for 10 days that resulted in approximately mid-luteal phase levels of progesterone (7.9–9.4 ng/mL; measured by ) did not cause any change in testosterone levels, suggesting that progesterone has little or no antigonadotropic effect in males at typical clinical dosages. In addition, a study found that administration of 1,000 mg/day oral
Pharmacokinetics of progesterone and has been found to result in higher serum peak progesterone levels relative to intramuscular oil formulations. In addition, subcutaneous injection of progesterone is considered to be easier, safer (less risk of injection site reactions), and less painful relative to intramuscular injection. The elimination half-life of this formulation is 13 to 18 hours, compared to 20 to 28 hours for intramuscular injection in oil. Progesterone has a very short elimination half-life of about 3 to 90 minutes when given by intravenous injection. A one-year progesterone intrauterine device (IUD) for hormonal birth control was previously available in the United States and